ABSTRACT
Background: Left ventricular global longitudinal strain (LV-GLS) has been recently demonstrated to be predictive of poor outcomes in various cardiovascular settings. Therefore, this study sought to investigate the prognostic implications of LV-GLS in patients with coronavirus disease 2019 (COVID-19). Method(s): This prospective study enrolled 180 consecutive hospitalized patients with COVID-19 admitted to a tertiary care hospital. LV-GLS from the apical four-chamber view was obtained using two-dimensional speckle-tracking echocardiography (2D-STE). Patients with diabetes, hypertension, heart failure, atrial fibrillation, and/or ischemic heart disease were excluded from the study. A correlation between LV-GLS and interleukin-6 (IL-6) levels, C-reactive protein (CRP) levels, in-hospital mortality, intensive care unit (ICU), and hospital stay were sought. Result(s): The mean age of included patients was 58 +/- 16 years. The mean left ventricular ejection fraction (LVEF) was 70.2 +/-6.5, the mean GLS was -21.9+/-4.3. Mean IL-6 and CRP were 9.9 +/- 7.8 pg/ml and 25.8 +/- 25.8 mg/dl respectively. Mean ICU and hospital stay were 7.5 +/- 3.14 and 10.7 +/- 4.03 days respectively. The in-hospital mortality rate was 2.22% (4 patients). Pearson correlation showed a negative correlation between LV-GLS and IL-6, CRP, ICU, and hospital stay (correlation coefficient r= -0.273, -0.301, -0.275, and -0.259 respectively). Conclusion(s): In an observational cohort study, LV-GLS had a negative correlation with laboratory and clinical outcomes in hospitalized COVID-19 patients. So far, long-term cardiovascular complications of COVID-19 are still unknown. Several reports indicate that GLS can be used as a validated method for early prediction of poor outcomes in COVID-19 patients even after the resolution of the original infection. [Formula presented]Copyright © 2023
ABSTRACT
Case Report Restless legs syndrome (RLS) is a poorly understood underdiagnosed neurological, sensorimotor disorder. RLS arises from central nervous system dysfunction leading to both sensory and motor symptoms. Limited cases of COVID-19 vaccines related neurological sequelae, such as Guillain-Barré syndrome (GBS), have been reported. Case presentation A 77-year-old male patient with a past medical history of well-controlled hypertension, diabetes mellitus, hypothyroidism, coronary artery disease status post percutaneous coronary intervention, obstructive sleep apnea on CPAP at night, and restless leg syndrome diagnosed 20 years ago, presented complaining of a 3-month history of worsening of his restless leg symptoms although being compliant with his medications 2 weeks after his 2nd dose of Moderna vaccine. He stated that the frequency and severity of his symptoms had increased from 3-4 times a week lasting for minutes to a daily basis lasting for hours at night, had improved partially with exercise, and affected his sleep hygiene and daily morning activities. He requested several refills of his previously prescribed ropinirole. A comprehensive evaluation, including clinical examination, laboratory workup, brain computed tomography, and polysomnography was unremarkable. He was commenced on pramipexole 0.5 mg daily and instructed to follow up in the clinic in 3 months and call back with no improvement or worsening of his symptoms. Conclusion This case fulfilled the four essential features of RLS, urge to move, worsening with rest, improvement with exercise, and worsening in the evening. To date, no case of RLS associated with COVID-19 vaccines has been previously reported. Although COVID-19 vaccines are relatively safe, long-term complications should be monitored closely.